Studies using conventional GVHD prophylaxis for MMUD HCTs
| Study . | Population . | Design . | Comparison . | Key findings . |
|---|---|---|---|---|
| Gupta et al (2010)7 | Poor-risk AML in CR1 underwent HCT from MSD (n = 226), 8/8 MUD (n = 254), and MMUD (n = 104) | CIBMTR—retrospective | NA | 1. Similar LFS and OS for MSD and 8/8 MUD transplants but LFS and OS were worse for MMUD HCT |
| Al Malki et al (2020)9 | 482 patients with hematologic malignancies underwent MUD/MMUD HCT with tacrolimus and sirolimus combination for GVHD prophylaxis | Single-institution retrospective study | NA | 1. 5-year OS: 39% for MMUD vs 50.7% for MUD, P = .022 2. NRM: 33.5% for MMUD vs 21.7% for MUD, P = .038 3. Severe GVHD: 20.8% for MMUD vs 12.8% for MUD, P = .22 4. Infection 33.0% for MMUD vs 18.1% for MUD, P < .01 5. No improvement in rates of relapse with MMUD HCT |
| Kornblit et al (2020)10 | 77 patients who underwent RIC PBSC HCT from MMUD for hematologic malignancies (76 evaluable patients) | Multicenter phase 2 trial | Historical | 1. Day 100 CI of grade II to IV aGVHD was 36% 2. OS at 4 years = 62% 3. NRM = 18% 4. Relapse/progression = 30% |
| Study . | Population . | Design . | Comparison . | Key findings . |
|---|---|---|---|---|
| Gupta et al (2010)7 | Poor-risk AML in CR1 underwent HCT from MSD (n = 226), 8/8 MUD (n = 254), and MMUD (n = 104) | CIBMTR—retrospective | NA | 1. Similar LFS and OS for MSD and 8/8 MUD transplants but LFS and OS were worse for MMUD HCT |
| Al Malki et al (2020)9 | 482 patients with hematologic malignancies underwent MUD/MMUD HCT with tacrolimus and sirolimus combination for GVHD prophylaxis | Single-institution retrospective study | NA | 1. 5-year OS: 39% for MMUD vs 50.7% for MUD, P = .022 2. NRM: 33.5% for MMUD vs 21.7% for MUD, P = .038 3. Severe GVHD: 20.8% for MMUD vs 12.8% for MUD, P = .22 4. Infection 33.0% for MMUD vs 18.1% for MUD, P < .01 5. No improvement in rates of relapse with MMUD HCT |
| Kornblit et al (2020)10 | 77 patients who underwent RIC PBSC HCT from MMUD for hematologic malignancies (76 evaluable patients) | Multicenter phase 2 trial | Historical | 1. Day 100 CI of grade II to IV aGVHD was 36% 2. OS at 4 years = 62% 3. NRM = 18% 4. Relapse/progression = 30% |
CR1, complete remission 1; NA, not available.